Kelun's TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer

Merck’s partner on an experimental antibody-drug conjugate has reported a Phase 3 win in first-line lung cancer, and will take the data to Chinese regulatory authorities. Chengdu-based Kelun-Biotech said that a combination of its ADC ...